Research
Hormonal
Adipose tissue functions as an active immunological organ during obesity, where expansion triggers chronic low-grade inflammation via immune cell infiltration and DAMP sensing, leading to systemic insulin resistance and metabolic syndrome.
Obesity is not just about storing excess calories; it triggers an immune response in fat tissue that causes insulin resistance. This means that simply losing weight without addressing the underlying inflammation might not fully restore metabolic health, and long-term weight maintenance is crucial to resolving this immune activation.
GoodSupportsHIGH confidence
The adipose tissue of obese subjects becomes inflamed and contributes to the development of insulin resistance, type 2 diabetes, and metabolic syndrome... obesity influences both the quantity and the nature of immune cell subtypes, which emerges as an active immunological organ capable of modifying whole-body metabolism through paracrine and endocrine mechanisms.
Why this rating
Based on a comprehensive review of multiple human and rodent studies, though specific clinical trial data is limited.
Source
Adipose tissue as an immunological organ
Ryan W. Grant et al. · Obesity · 2015
DOI 10.1002/oby.21003
narrative_reviewCited 439×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Macrophage polarization from anti-inflammatory M2 to pro-inflammatory M1 phenotypes in adipose tissue is a key driver of insulin resistance, driven by the sensing of metabolic danger signals (DAMPs) like free fatty acids and uric acid.Good
- Obesity impairs the immune response to pathogens, increasing susceptibility to severe infections like influenza, due to defects in T cell development, function, and vaccine efficacy.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →